All News

The agreement marks the second cell line development collaboration between the two companies

The expansion close to company's Martinsried headquarters includes a lyophilisation development centre for advanced therapy medicinal products

The market for CBD is growing and it is not just the pharmaceutical industry that is exploring its potential. Martin Oxley, MD at buzzback UK explains how consumer interest in plant-based ingredients and natural products present huge opportunities for ...

Dr. Paul Lohmann® recently received a CEP (Certificate of Suitability to the European Pharmacopoeia) for Monosodium Phosphate 2-hydrate, which enables a customer to register a drug in several countries in a cost-saving and simplified way. Since thi...

Ahead of Pharmapack Europe 2021 in October, we talk to one of the speakers, Serkan Oray, Vice President, Devices, Packaging & Wearable Technologies at UCB Pharma about the company's new electromechanical injection device and the innovation drive wi...

While the COVID-19 pandemic has created even greater demand for partnerships, CDMOs need to be aware that the needle has shifted, creating both opportunities and challenges and changing how the services industry does business

While in the past, much of the discussion around sustainability in the pharmaceutical industry rightly focused on efforts to minimize the environmental impact of drug production, the needle has now shifted. There are signs that companies not only under...

The company expects to complete its building and modernising plans in Turku by 2025

Drug categories impacted by travel restrictions expected to see higher sales levels in FY22

The French CDMO is also creating a new global resource for drug developers of ATMPs

During CPHI Discover (17th-28th May, 2021) – global pharma’s largest ever virtual gathering – we spoke with Doug Hausner, Senior Manager Continuous Manufacturing at Thermo Fisher Scientific. He presented his views on how continuous ma...

XDC will provide a full range of development and manufacturing services in one centralised region

Biogen and Eisai's Aduhelm approved using the accelerated approval pathway after clinical trials demonstrated it reduced amyloid beta plaques by up to 71%

The expanded capacity and capabilities include the development of a dedicated Life Sciences Technology Center

New $30 million manufacturing facility in Burlington, Ontario, will allow company to manage R&D in-house and scale production without reliance on third-party manufacturers

The initial outbreak of the COVID-19 pandemic delayed merger and acquisitions in the pharma sector, but evidence points to an uptick in activity because the rationale for sealing deals hasn’t changed

CPHI Discover (May 17-28) gave Pharma companies, suppliers and service providers the opportunity to keep potential buyers and partners abreast of the latest news, product information and market trends in the form of free-to-access, downloadable content...

Alliance to Zero aims to facilitate the transition of the pharma sector to reach net zero emissions target

Drug substance production line expected to be operational by end of 2021 as part of CDMO’s expanded collaboration with biotech

Cytokine storm is a main cause of worsening and death of COVID-19 patients. Techpool UTI inhibits the release of Inflammatory Cytokines and blocks Cytokine Storm in time to treat COVID-19 patients.

Hameln plant which provides fill and finish for Pfizer-BioNTech COVID-19 shot should be fully operational within the week, CDMO says

A new location in Raleigh-Durham, North Carolina, close to the CDMO's Center of Excellence, will double its current footprint

The specialist CDMO receives manufacturing licenses from Switzerland and Denmark to supply customers with live biotherapeutic medicines

The latest coronavirus updates and developments impacting the global pharmaceutical supply chain (continued from here)

The company's new synthetic cholesterol product will help meet the demand for mRNA vaccines, including Pfizer-BioNTech Covid-19 Vaccine

The purchase is part of $17 million capacity expansion, which is in addition to a wider $43 million investment into the company's Pennsylvania operations

CPHI Discover webinar examines the progress made so far in terms of vaccine distribution to the global population as well as anticipating future challenges

CPHI Discover panel of industry experts discusses impact of COVID-19 on API manufacturing and trading as well as the controversial topic of reshoring production

Upstream raw materials suppliers seen as the main source of innovation in a growing industry driven by demand for more natural ingredients manufactured in clean, sustainable way

Bookmark this page for regular updates on the rich variety of content coming your way via CPHI Discover, pharma’s largest ever virtual gathering, over the course of our three-day agenda

Partnering with one of northern Europe’s oldest academic universities, Lund University in Sweden, Pharmapack has launched this three-part podcast series, delivering the latest insights on medication packaging innovation and the gathering momentum...

Extending its patient-centric BD Intevia™ Disposable Autoinjector platform, BD builds on past successes while meeting the requirements of new, highly viscous, high-volume biologics for chronic diseases

Dosing complexity means programmable devices need to address several requirements around wearability and flexibility, CPHI Discover delegates are told

Pre-fillable syringes for intravenous drugs can replace traditional glass vials and ampoules, particularly in the time-sensitive and fast-paced world of emergency care

Coronavirus pandemic has exacerbated manufacturing capacity constraints, particularly in injectable dose and viral vector production, CPHI audience told

Strong and effective partnerships with CDMOs are essential to success due to the complexity of manufacturing processes

Process of identifying new uses for approved drugs can be done through different pathways and can yield some surprising benefits

The UK’s withdrawal from the European Union has meant the pharmaceutical industry has had to adapt to some monumental changes in terms of research, regulatory affairs, and trade. In this CPHI Webinar, three industry experts discussed what the fut...

Zaragoza plant will produce devices such as prefillable syringes to deliver vaccines and other biologics

CDMO's site becomes the first vaccine production facility in South Korea to obtain EU GMP certification, allowing it to ship to Europe

Our virtual CPHI Discover event (17th-28th May) is just around the corner, full to the brim with three main content tracks. Here, we explore the major trends in APIs, Ingredients & Formulation

Our virtual CPHI Discover event (17th-28th May) is just around the corner, full to the brim with three main content tracks. Here, we explore the major trends in Drug Delivery and Packaging.

The CDMO's expertise and capabilities a "perfect fit" for overcoming the challenges of manufacturing this complex molecule

Our virtual CPHI Discover event (17th-28th May) is just around the corner, full to the brim with three main content tracks. Here, we explore the major trends and issues surrounding Manufacturing and Outsourcing.

New facility at Gosselies site will host commercial scale pDNA manufacturing as Catalent extends its cell and gene therapy footprint

Step inside our state-of-the-art plant to learn about our small molecules CDMO services and meet our team with a virtual tour that focuses on your areas of interest.

Read this new CPHI Trend Report which, via interviews with key industry experts, explores the state of India's API manufacturing issue and how it is being impacted by the country's ambitious healthcare reform programme as well as efforts by the governm...

In the future pharma companies will need to work closer with excipient companies if we are to develop better formulations more quickly

The addition of two new manufacturing trains will support the demand for high-value biopharmaceutical products

Industrial assets purchaser is offering high-capacity production line equipment formerly owned by bankrupt CMO

The expansion will support a 50% increase in production of biotech's COVID-19 vaccine at its manufacturing site

Ahead of the session, How will the New Administration Impact the US Pharma Market? at CPHI Discover on Tuesday 18th May – global pharma’s largest ever virtual gathering – we spoke with one of the speakers, Nielsen Hobbs...

Transaction enables ArchiMed-backed biopharmaceutical services group to establish North American presence and expand activities with complementary services

Ahead of the session, Value Added Excipients to Unlock the Potential of APIs, at CPHI Discover on Thursday 18th May – global pharma’s largest ever virtual gathering – we spoke with one of the speakers, Dr Iain Moor...

Our online pharma event CPHI Discover is almost upon us! While we’ll be delving into the typical themes of ingredients, manufacturing, supply chain logistics and technology, we’re also going to be examining some newer trends which are impac...

The software consulting company claims its software solution has already saved one pharma company €10.5 million

Biotech ties up deal three days after World Health Organization issued an emergency use listing for the mRNA vaccine

To remain competitive, pharma companies must now collaborate with suppliers on how their packaging processes address sustainability. This recent webinar available on demand provides an overview on the drive for sustainable development and improving the...

How is the pharmaceutical industry tackling the issue of ensuring minority populations are properly represented in clinical trials?

Three additional drug substance manufacturing lines will be added to existing ones at Swiss site and are expected to be operational in early 2022

CPHI asks industry experts at Beximco Pharmaceuticals, Catalent, DIA and Thermo Fisher Scientific to weigh in on the remarkable innovations we have witnessed and what lasting impacts they may have on our industry in a post-pandemic world

Sweeping ban includes APIs, intermediates and prescription and OTC medicines and comes amid tight regulatory requirements and the "high risk nature" of pharma products, e-commerce giant says

The new business alliance will support new product launches for specialty pharmaceutical manufacturers looking to enter the Japanese market

French company is now providing manufacturing capacity to support three different COVID-19 vaccines

CHF 200 million investment will include dedicated line for antibody-drug conjugate payload molecules and is scheduled to start operations in Q3 2023

With CPHI North America fast approaching, we ask Karen Flynn (President, Biologics & Chief Commercial Officer, at Catalent), Hamilton Lenox (Senior Vice President of Business Development, Sales & Marketing, at LGM Pharma), and Mike Kleppinger, Chief Co...

What are the major implications of any drive to reshore US pharmaceutical manufacturing, given that current Asian domination is based on cost savings and capacity? We ask the experts...

Company failed to investigate vaccine drug substance discrepancies thoroughly, says US regulator

2020 will go down in history as a pivotal year for the US pharmaceutical manufacturing sector. Firstly, the emergence of the global coronavirus pandemic provided a seismic shock to the industry and forced major rethinking on several lines. And secondly...

Agency’s safety committee concludes positive benefit-risk profile but orders warning about rare blood clots to be added to shot’s product information

The company will expand multiple facilities in Hyderabad and Bangalore to help reach its target of approximately 700 million doses per year of the COVID-19 vaccine

Ahead of CPHI Discover (17-28 May, 2021) - global pharma's largest ever virtual gathering - we spoke to CPHI Annual Report expert Vicky Xia, China Head at BioPlan Associates on the biologics trends she is seeing emerging in the contract services sp...

Sustainability takes effort, but the benefits of economically viable, environmentally responsible operations are worth it, even for smaller drug companies

The expanded agreement will ensure Rocket Pharma's supply of lentiviral vectors across its pipeline

Extra supply will bring total number of doses scheduled to be shipped to EU this year to 600 million

The expansions will enable the company's local customers to test equipment directly at the manufacturing site

New facility will be research partnering company’s sixth global site and will be dedicated to mammalian biologics

Informa Markets' first in-person trade show of the year welcomes attendees in Tokyo as face-to-face interaction recommences among pharma community

See MTI Bioscience systems in action! MTI Bioscience is excited to demonstrate their Continuous Thermal Sterilizers live on Zoom®. Please attend the following free live events on May 5th and 12th at 11 am EST, hosted by Dr. John Miles, President of...

The antibody-based products will be expressed using Lonza's GS Xceed Gene Expression System

The concept of Green Chemistry first arose as a set of principles to minimize the environmental impact of chemical production but as one of its earliest adopters, the pharmaceutical industry has enjoyed several other benefits

The company will invest €400 million in a new site to enable it to produce vaccines on a massive scale for Asia

The global CMO plans to have a complete, licensed cGMP manufacturing facility online by the end of 2021

The company's custom single run single-use fermenters supplied on fast-track schedule to support flexible manufacturing of plasmid DNA

The smallpox vaccine specialist will manufacture and deliver bulk drug substance of MVA-BN Filo vaccine during the second half of this year

Increased range of sizes and available features, plus new options in ANFD systems and the popular Benchtop Nutsche Filter for scaleup and kilogram level production

Pharmaceuticals discarded in the environment pose a risk to fish and other wildlife, for example by affecting their ability to reproduce, by altering their behaviour in ways jeopardising their survival, or through direct toxic effects. Increased awaren...

The extended collaboration comes after reaching the initial milestone of producing 100 million doses

By integrating its HPAPI capabilities with those at ADC Biotechnologies' Deeside facility, small molecule CDMO will be able to offer the development and manufacturing of toxin linkers

Ploermel and Edinburgh facilities employ around 390 permanent staff and will allow UK CDMO to expand its technology offering

Facility will support UK-based crystal and particle engineering specialist's existing Chinese subsidiary to expand product development services

The US facility in Rockville is expected to accelerate the company’s commercial-scale manufacturing timelines of gavo-cel

The CDMO will provide cell line development, process development, drug substance and drug product manufacturing for Pionyr’s monoclonal antibody candidate

The former Rohner's manufacturing assets will enable omega-3 heavyweight to manufacture difficult, multi-step pharmaceutical intermediates and APIs

Pharma company will provide fill and finish manufacturing capacity at its Barnard Castle facility as early as the beginning of May 2021

Innovation in the design and development of large volume drug delivery devices can solve the challenge of accommodating the increasing trend towards patient self-administration and home care while at the same time ensuring that drugs that require intra...

Some seaborne deliveries are being rerouted or switched to air transportation as efforts to re-float stricken Ever Given container vessel move into fourth day

New site includes warehouse maagement system which packaging firm claims will increase picking accuracy and efficiency

While research and development (R&D) in the pharma sector has traditionally been largely constrained to in-house activity, companies are now much more open to the idea of outsourcing their innovation to remain competitive amid spiralling costs of drug ...

Company will use extension of Schedule I licence to start development of psychedelics-based pipeline to treat mental health disorders

The company will triple its capacity and workforce at its North Carolina site to increase its global capabilities and reach

A quarterly series of blog posts about responsible supply chain management from the PSCI Chair, Manjit Singh

Partnering with one of northern Europe’s oldest academic universities, Lund University in Sweden, Pharmapack has launched this three-part podcast series, delivering the latest insights on medication packaging innovation and the gathering momentum...

The CDMO's Zydis technology will help the Canadian biotech to develop fast-acting, shorter-duration formulations of its potential therapy for treatment-resistant psychiatric disorders

CDMO subsidiary Fujifilm Diosynth Biotechnologies will operate the site which is expected to be operational in 2025

Pharma’s uptake of continuous manufacturing is slowly gaining traction as the technology does hold some key advantages over traditional batch manufacturing, such as the potential to realise cost savings and the promise of lower yield loss.

EU/UK trade deal fell way short of UK’s initial expectations for medicinal products ahead of negotiations, says Peter Gough at NSF International

Multinational makes ‘difficult decision’ to halt presence in Chinese biosimilars market five years after $350 million investment

Despite COVID-related challenges and supply chain issues, the CDMO's $240 million new facility is on target to open next year

AI is helping pharma find the drug candidates with the greatest chance of success, according to experts who say therapeutic efficacy and cost reduction are the key dynamics

The move ensures the service provider has the capacity to meet the needs of an evolving clinical market

US-headquartered company Kindeva seals deal for an R&D facility at Loughborough’s life sciences hub

Excipients are a crucial component of the pharmaceutical product formulation, and the industry is constantly having to adapt to changes in demand and technology innovations

Adaptive clinical trials have accelerated COVID-19 vaccine development and could make drug R&D more efficient but running such studies is complex and challenging and sponsors need to prepare, say experts

Regulators stress temporary halt is precautionary measure and that there is currently no evidence linking the shot to adverse events

Tremendous growth opportunities exist for auto-injectors as their value is increasingly being recognised across several therapy areas, experts have told a recent CPHI webinar, sponsored by Stevanato Group.

What are APIs? As the name suggests, Active Pharmaceutical Ingredients (APIs) are the heart of any dosage form, whether they are oral, injectable or inhaled, and are absolutely essential to the development of a formulated product.

The purchase will allow the company to add nine new customers to its growing CDMO business and 27 manufacturing suites

In this special roundtable podcast exploring potential opportunities in a post-vaccinated world, we are joined by a panel of three world class experts – Bikash Chatterjee, CEO of Pharmatech Associates; Parrish Galliher, Managing Director, Bi...

Biologic products advance through clinical development with a higher success rate than traditional small molecules, this new analysis of clinical development success from Informa Pharma Intelligence, the Biotechnology Industry Organization and the...